StockTipsArenaBeta

BUY Lupin Limited — Laxmikant Shukla, YES Securities

BUYLupin Limited

byLaxmikant Shukla, YES SecuritiesHorizon: NA (inferred Swing (≤2wk))6 May 2026via ET Now

Entry₹2,400Stated
Target₹2,600
Total upside +8.33% (call closed)
Stop loss₹2,300-4.17% risk
Exit₹2,30011 May 2026, 9:15 am
Stop-loss hit-4.17%
Follow Laxmikant Shukla for new calls(33% target hit, 91 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 106 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 7:00 pm IST
4 supporting1 neutral0 opposing
Supports the BUY call (4)

Lupin Limited announced its audited financial results for FY2026 and Q4 FY2026. The company reported a significant increase in sales and EBITDA, with a recommended dividend of 900%.

NSE · Press Release·7 May · 3d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·6 May · 4d ago

Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its Glycerol Phenylbutyrate Oral Liquid.

BSE · Company Update·5 May · 6d ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·4 May · 6d ago

Neutral / worth noting (1)

The Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each ....

BSE · Board Meeting·7 May · 3d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.